LiteVax BV
Litevax BV is a biopharmaceutical company dedicated to developing and exploiting innovative vaccine adjuvant concepts. Their mission is to improve vaccines against infectious and noninfectious diseases, benefiting people worldwide with better vaccines at lower costs.
Industries
Nr. of Employees
small (1-50)
LiteVax BV
Patents
Products
cGMP aqueous adjuvant formulation (synthetic carbohydrate-based)
A ready-for-use aqueous vaccine adjuvant formulation comprising a synthetic carbohydrate fatty acid monosulphate ester immobilized on squalane-in-water nano-emulsion, produced under cGMP for preclinical and clinical use.
cGMP aqueous adjuvant formulation (synthetic carbohydrate-based)
A ready-for-use aqueous vaccine adjuvant formulation comprising a synthetic carbohydrate fatty acid monosulphate ester immobilized on squalane-in-water nano-emulsion, produced under cGMP for preclinical and clinical use.
Services
Collaborative development programs with public and private partners to evaluate adjuvanted vaccine concepts across discovery, preclinical and early clinical phases.
Provision of ready-for-use aqueous adjuvant formulations manufactured under cGMP for use in preclinical experiments and clinical trials.
Support for process and product development, technology transfer into manufacturing and project management for biopharmaceutical products.
Collaborative development programs with public and private partners to evaluate adjuvanted vaccine concepts across discovery, preclinical and early clinical phases.
Provision of ready-for-use aqueous adjuvant formulations manufactured under cGMP for use in preclinical experiments and clinical trials.
Support for process and product development, technology transfer into manufacturing and project management for biopharmaceutical products.
Expertise Areas
- Vaccine adjuvant design and optimization
- Preclinical immunogenicity and toxicology studies in non-rodent species
- Early-phase clinical trial management (Phase I/II) for vaccines
- cGMP manufacturing and formulation of adjuvant products
Key Technologies
- Synthetic carbohydrate fatty acid monosulphate ester adjuvants
- Squalane-in-water nano-emulsion formulation
- Aqueous adjuvant formulations for clinical use
- Preclinical animal models (large non-rodent species)
News & Updates
Promising Preclinical data on CMS in combination with PCV, showing vaccine improvement of the current Pneumococcal Conjugate Vaccines, in collaboration with Radboud University Medical Center.
Advancing LiteVax’s adjuvant technology into the clinic, with a focus on improved influenza vaccines, in collaboration within the INDIGO consortium.
A follow-up of the first-in-human trial evaluating safety, immunogenicity, and mechanisms of a novel LiteVax Adjuvant added to licensed influenza vaccine in participants aged 18-50 and > 60 years.
Development of a vaccine targeting Urinary Tract Infections in collaboration with partners, focusing on a novel bacterial vaccine concept.
A Phase 1 trial with a low-dose seasonal influenza vaccine using LiteVax’s adjuvant, assessing safety and immunogenicity.
Next Generation Vaccines for Multi-Resistant Bacteria, focusing on C. difficile.
Promising Preclinical data on CMS in combination with PCV, showing vaccine improvement of the current Pneumococcal Conjugate Vaccines, in collaboration with Radboud University Medical Center.
Advancing LiteVax’s adjuvant technology into the clinic, with a focus on improved influenza vaccines, in collaboration within the INDIGO consortium.
A follow-up of the first-in-human trial evaluating safety, immunogenicity, and mechanisms of a novel LiteVax Adjuvant added to licensed influenza vaccine in participants aged 18-50 and > 60 years.
Development of a vaccine targeting Urinary Tract Infections in collaboration with partners, focusing on a novel bacterial vaccine concept.
A Phase 1 trial with a low-dose seasonal influenza vaccine using LiteVax’s adjuvant, assessing safety and immunogenicity.
Next Generation Vaccines for Multi-Resistant Bacteria, focusing on C. difficile.